Usefulness of quantitative bone SPECT/CT for medication-related osteonecrosis of the jaw in clinical settings

被引:10
|
作者
Moridera, Kuniyasu [1 ]
Kitajima, Kazuhiro [2 ]
Yoshikawa, Kyohei [1 ]
Takaoka, Kazuki [1 ]
Tsuchitani, Tatsuya [3 ]
Noguchi, Kazuma [1 ]
Kishimoto, Hiromitsu [1 ]
Yamakado, Koichiro [2 ]
机构
[1] Hyogo Coll Med, Dept Oral & Maxillofacial Surg, Mukogawa Cho 1-1, Nishinomiya, Hyogo 6638501, Japan
[2] Hyogo Coll Med, Dept Radiol, Nishinomiya, Hyogo, Japan
[3] Hyogo Coll Med Coll Hosp, Dept Radiol Technol, Nishinomiya, Hyogo, Japan
关键词
Medication-related osteonecrosis of the jaw (MRONJ); Bone SPECT; CT; SUV; Metabolic bone volume (MBV); BISPHOSPHONATE-RELATED OSTEONECROSIS; MANAGEMENT;
D O I
10.1007/s11604-021-01226-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective This study was conducted to investigate the clinical utility of quantitative bone single-photon computed tomography-computed tomography (SPECT/CT) for detection and classification for medication-related osteonecrosis of the jaw (MRONJ). Materials and methods Fifty-nine patients (69 lesions) clinically diagnosed as MRONJ by four specialists of Japanese Society of Oral Surgery according to the AAOMS diagnostic criteria and who underwent bone SPECT/CT were enrolled. One reader determined standard uptake values (SUVs), including maximum (SUVmax), peak (SUVpeak), and mean (SUVmean), as well as metabolic bone volume (MBV), representing total volume above threshold, and total bone uptake (TBU), calculated as MBV x SUVmean, using the GI-BONE software package. One-way repeated-measures analysis of variance and subsequent post hoc analysis were employed to compare quantitative values between clinical stages. To check reproducibility of values, another reader calculated these quantitative values. Results Mean SUVmax values for stage 0 (n = 21), 1 (n = 13), 2 (n = 25), and 3 (n = 10) were 5.82 +/- 3.20, 5.46 +/- 3.79, 8.16 +/- 3.93, and 10.57 +/- 8.43, respectively, while values for MBV were 9.52 +/- 6.33, 11.36 +/- 7.32, 12.4 +/- 8.21, and 17.84 +/- 16.94, respectively, and for TBU were 40.60 +/- 46.97, 53.70 +/- 77.26, 62.37 +/- 42.91, and 102.01 +/- 74.52, respectively. There were significant differences for SUVmax, SUVpeak, and SUVmean between clinical stages (p = 0.024, p = 0.027, p = 0.039, respectively). Subsequent post hoc analysis showed that SUVmax and SUVpeak of stage 3 were significantly higher than those of stage 0 (p = 0.046, 0.045, respectively). MBV and TBU showed a tendency to increase with increased stage, though differences between stages were not significant (p = 0.15, p = 0.053, respectively). Little differences of mean SUVmax, SUVpeak, SUVmean, MBV, and TBU between two readers were observed (- 3.10%, - 0.26%, - 4.24%%, 0.69%, and - 3.42%, respectively). The intraclass correlation coefficients (ICCs) of SUVmax, SUVpeak, SUVmean, MBV, and TBU were 0.985, 0.990, 0.980, 0.994, and 0.994, respectively (almost perfect for all values). Conclusion As objective and reliable indicators, SUVmax and SUVpeak derived from quantitative bone SPECT/CT results are useful for detection of early status disease, as well as staging in MRONJ patients.
引用
收藏
页码:492 / 499
页数:8
相关论文
共 50 条
  • [1] Usefulness of quantitative bone SPECT/CT for medication-related osteonecrosis of the jaw in clinical settings
    Kuniyasu Moridera
    Kazuhiro Kitajima
    Kyohei Yoshikawa
    Kazuki Takaoka
    Tatsuya Tsuchitani
    Kazuma Noguchi
    Hiromitsu Kishimoto
    Koichiro Yamakado
    Japanese Journal of Radiology, 2022, 40 : 492 - 499
  • [2] Usefulness of quantitative bone SPECT/CT for evaluating medication-related osteonecrosis of the jaw treatment response
    Kuniyasu Moridera
    Kazuhiro Kitajima
    Kyohei Yoshikawa
    Kazuki Takaoka
    Tatsuya Tsuchitani
    Kazuma Noguchi
    Hiromitsu Kishimoto
    Koichiro Yamakado
    Japanese Journal of Radiology, 2023, 41 : 760 - 767
  • [3] Usefulness of quantitative bone SPECT/CT for evaluating medication-related osteonecrosis of the jaw treatment response
    Moridera, Kuniyasu
    Kitajima, Kazuhiro
    Yoshikawa, Kyohei
    Takaoka, Kazuki
    Tsuchitani, Tatsuya
    Noguchi, Kazuma
    Kishimoto, Hiromitsu
    Yamakado, Koichiro
    JAPANESE JOURNAL OF RADIOLOGY, 2023, 41 (07) : 760 - 767
  • [4] Quantitative Analysis of Multimodal Skeletal SPECT/CT Reconstructions in Diagnosing Medication-related Osteonecrosis of the Jaw
    Beck, Michael Thomas
    Rugel, Gregor
    Reinfelder, Julia
    Kuwert, Torsten
    Ritt, Philipp
    Kreissel, Sebastian
    Schlittenbauer, Tilo
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2021, 60 (06): : 403 - 410
  • [5] Medication-Related Osteonecrosis of the Jaw
    Chen, Yu-Feng
    Chang, Hong-Po
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (21): : E69 - E69
  • [6] Medication-related Osteonecrosis of the Jaw
    Matys, Tomasz
    RADIOLOGY, 2021, 301 (03) : 548 - 548
  • [7] Medication-Related Osteonecrosis of the Jaw
    Ohta, Keiichi
    Yoshimura, Hitoshi
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2020, 360 (03): : 316 - 317
  • [8] Clinical utility of three-dimensional SPECT/CT imaging as a guide for the resection of medication-related osteonecrosis of the jaw
    Miyashita, H.
    Shiba, H.
    Kawana, H.
    Nakahara, T.
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2015, 44 (09) : 1106 - 1109
  • [9] Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw
    Son, Hyo-Jeong
    Kim, Jin-Woo
    Kim, Sun-Jong
    MAXILLOFACIAL PLASTIC AND RECONSTRUCTIVE SURGERY, 2019, 41 (01)
  • [10] Medication-related osteonecrosis of the jaw: Clinical and practical guidelines
    Rosella, Daniele
    Papi, Piero
    Giardino, Rita
    Cicalini, Emauele
    Piccoli, Luca
    Pompa, Giorgio
    JOURNAL OF INTERNATIONAL SOCIETY OF PREVENTIVE AND COMMUNITY DENTISTRY, 2016, 6 (02): : 97 - 104